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Introduction
The extracellular matrix (ECM) of  the airways and lung is a dynamic structure composed of  a diverse 
set of  proteins, glycoproteins, and lipids that provides architectural support and contributes to biological 
processes in these tissues. Remodeling of  the ECM occurs continuously and is tightly controlled to maintain 
homeostasis through the production of  proteins including fibronectin (Fn), fibulin (Fbln), periostin 
(Postn) and tenascin-c (Tnc), as well as their degradation by matrix (matrix metalloproteases; MMPs) and 
disintegrin and metalloproteinase with thrombospondin motifs (a disintegrin and metalloproteinase with 
thrombospondin motif; ADAMTS) metalloproteases (1). Disruption of  homeostatic remodeling processes 
through changes in the levels and spatial and temporal production of  ECM proteins leading to tissue 
remodeling is an important feature of  chronic respiratory disease and other diseases.
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that is primarily caused 
by cigarette smoke–induced (CS-induced) chronic inflammation in Western societies (2–4). CS exposure 
also induces airway epithelial and mesenchymal cells to produce excessive amounts of  ECM proteins (5). 
This also promotes COPD pathogenesis by causing airway remodeling and disrupting interstitial tissue and 
alveolar integrity. These events lead to airway narrowing, parenchymal damage, emphysema, and impaired 
lung function (6). Accumulation of  ECM also occurs in specific regions of  the lungs in asthma and 
Airway and/or lung remodeling, involving exaggerated extracellular matrix (ECM) protein 
deposition, is a critical feature common to pulmonary diseases including chronic obstructive 
pulmonary disease (COPD), asthma, and idiopathic pulmonary fibrosis (IPF). Fibulin-1 (Fbln1), 
an important ECM protein involved in matrix organization, may be involved in the pathogenesis 
of these diseases. We found that Fbln1 was increased in COPD patients and in cigarette smoke–
induced (CS-induced) experimental COPD in mice. Genetic or therapeutic inhibition of Fbln1c 
protected against CS-induced airway fibrosis and emphysema-like alveolar enlargement. In 
experimental COPD, this occurred through disrupted collagen organization and interactions with 
fibronectin, periostin, and tenascin-c. Genetic inhibition of Fbln1c also reduced levels of pulmonary 
inflammatory cells and proinflammatory cytokines/chemokines (TNF-α, IL-33, and CXCL1) in 
experimental COPD. Fbln1c–/– mice also had reduced airway remodeling in experimental chronic 
asthma and pulmonary fibrosis. Our data show that Fbln1c may be a therapeutic target in chronic 
respiratory diseases.
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idiopathic pulmonary fibrosis (IPF) (7, 8). Targeting ECM proteins may have beneficial effects; however, 
current therapies have limited efficacy in controlling tissue remodeling, and new therapeutic targets and 
strategies are urgently needed.
Fbln1 is a secreted glycoprotein (9) that stabilizes ECM integrity through interactions with other ECM 
proteins (10, 11). Four Fbln1 variants (Fbln1a/b/c/d) have been identified with differences in C-terminal 
sequences. It is difficult to study the levels of  different Fbln1 isoforms in human disease since antibodies to 
the specific isoforms are not available. Only Fbln1c and -d are found in both humans and mice (12). Fbln1c, 
but not -d, is implicated in airway remodeling and is specifically induced by TGF-β treatment of  airway 
smooth muscle (ASM) cells (13).
Fbln1 is known to play important roles in wound repair (13, 14) and is associated with several 
respiratory diseases. Increased levels of  Fbln1 occur in serum and bronchoalveolar lavage fluid (BALF) of  
asthma patients, and inhibition of  Fbln1c expression by antisense oligonucleotide reduced the proliferation 
of  ASM cells from these patients (13). In IPF, ECM proteins are increased in both plasma and lung tissue 
(15), and Fbln1c variant–specific peptide increases the proliferation of  lung fibroblasts, the main producers 
of  ECM, in COPD and IPF patients (14). Cytokines associated with lung diseases, such as TGF-β, that are 
known to induce ECM proteins (16) also stimulate Fbln1 production in ASM cells from COPD patients, 
further indicating roles for Fbln1 in airway remodeling (17). Nevertheless, the in vivo function of  Fbln1 in 
tissue remodeling in chronic pulmonary diseases is poorly understood.
In this study, we demonstrate that Fbln1 plays major roles in the pathogenesis of  airway and lung 
remodeling in experimental COPD, asthma, and pulmonary fibrosis. Genetic or therapeutic inhibition of  
Fbln1c in experimental COPD prevented or reversed the development of  CS-induced airway remodeling, 
emphysema-like alveolar enlargement, and inflammation, resulting in improved lung function. Targeting 
Fbln1 may therefore be beneficial in chronic respiratory disease and other diseases.
Results
Fbln1 is increased in primary bronchoepithelial cells (pBECs) from COPD patients. pBECs were obtained from 
COPD patients, non-COPD smokers, and nonsmoking healthy controls and were cultured. Proteins were 
extracted from cell lysates, and Fbln1 levels were measured by immunoblot. Fbln1 protein levels were 
significantly increased in the pBECs from COPD patients compared with both healthy controls and non-
COPD smokers (Figure 1A). Levels were also increased in the serum of  COPD patients compared with 
healthy controls (Figure 1B).
Chronic CS exposure induces airway and lung remodeling in experimental COPD in mice. The effect of  CS 
exposure on airway and lung remodeling was determined by assessing collagen levels in whole lungs 
and around the small airways in our well-established model of  experimental COPD in C57BL/6 mice 
(18–22). In those and the current studies, we have shown extensively that 8 weeks of  CS exposure 
resulted in the development of  experimental COPD with airway and lung inflammation and remodeling, 
emphysema (increased alveolar diameter), and impaired lung function (as shown in subsequent Figures). 
These events were associated with reduced levels of  total collagen in whole lungs compared with normal 
air–exposed mice determined by collagen-specific amino acid hydroxyproline analysis (Figure 1C). 
Soluble collagen levels were also significantly decreased. ECM gene array and quantitative PCR (qPCR) 
showed that the mRNA levels of  type I collagen-α1 (Col1a1), the most abundant collagen, and Col5a1 
were lower in CS-exposed mice compared with normal air–exposed control mice (Supplemental Figure 
1A and Supplemental Table 1; supplemental material available online with this article; doi:10.1172/jci.
insight.86380DS1). These reductions are likely due to emphysema and loss of  tissue. In contrast, collagen 
deposition around the small airways was significantly increased (Figure 1D).
Fbln1 protein levels in whole lungs and around small airways were significantly increased after 8 weeks 
of  CS exposure but not at earlier timepoints (Figure 1, E and F). The histology showed that Fbln1c was 
produced in the airway epithelium after 6 weeks and then deposited around the airways after 8 weeks. This 
shows associations of  increased Fbln1 concomitant with the development of  disease features in experimental 
COPD, which replicated the increased levels of  Fbln1 in the airways/lung tissues of  COPD patients. How-
ever, Fbln1c and Fbln1d mRNA expression levels in lungs were not affected by experimental CS exposure 
(Supplemental Figure 1, B and C). Serum levels of  Fbln1 protein were also increased in experimental COPD 
(Figure 1G), as they were in human patients.
Generation of  Fbln1c–/– mice. Deletion of  all variants of  Fbln1 in mice results in perinatal lethality 
Downloaded from http://insight.jci.org on February 28, 2017.   https://doi.org/10.1172/jci.insight.86380
3insight.jci.org   doi:10.1172/jci.insight.86380
R e s e a R c h  a R t i c l e
Downloaded from http://insight.jci.org on February 28, 2017.   https://doi.org/10.1172/jci.insight.86380
4insight.jci.org   doi:10.1172/jci.insight.86380
R e s e a R c h  a R t i c l e
(23, 24). To assess the role of  Fbln1 in COPD pathogenesis, we generated mice deficient in the Fbln1c 
isoform using a gene-targeting strategy. A Fbln1c-specific targeting vector was generated (Figure 2, A–C) 
and transfected into embryonic stem cells (ES cells) to specifically delete this isoform. After injection 
of  recombinant ES cells into C57BL/6 mice, the Fbln1c gene was deleted in the offspring, confirmed by 
Southern blot and qPCR analyses (Figure 2, D–G). Fbln1c–/– mice displayed no developmental abnormalities 
(unpublished observation) or baseline differences in airway remodeling or inflammation (Figure 3).
Deletion of  Fbln1c in mice inhibits airway and lung remodeling and protects against experimental COPD. WT and 
Fbln1c–/– C57BL/6 mice were exposed to CS or normal air for 8 weeks, and the amount of collagen in lung 
tissue assessed. The decreases in total and soluble collagen levels, as well as Col1a1 protein in experimental 
COPD, were prevented in Fbln1c–/– mice (Figure 3, A and B). Fbln1c–/– mice were also completely protected 
from increased collagen deposition around the small airways (Figure 3, C and D and Supplemental Figure 
2A). WT mice also had increased α-smooth muscle actin–positive (α-SMA–positive) cells around the small 
airways after CS exposure, whereas Fbln1c–/– mice did not (Figure 3E). Emphysema-like alveolar enlargement 
was partially inhibited in CS-exposed Fbln1c–/– mice compared with WT mice (Figure 3F and Supplemental 
Figure 2B). Furthermore, CS-exposed Fbln1c–/– mice were also protected against changes in lung function, with 
no increase in lung volume (Figure 3G) or static lung compliance (Figure 3H) compared with WT controls.
Since global deletion of  Fbln1c suppresses COPD pathogenesis, we assessed whether intranasal treatment 
with a specific siRNA targeting Fbln1c had therapeutic effects. Mice were administered Fbln1c or scrambled 
siRNA every 2 days during acute (4-day) CS exposure or from weeks 6–8 of  chronic (8-week) CS exposure. 
These are the periods when Fbln1c mRNA expression first increases and fibrosis emerges, respectively. The 
efficiency of  Fbln1c knockdown by siRNA was tested in mouse lungs. siRNA treatment significantly reduced 
Fbln1c expression after acute and chronic CS exposure, but Fbln1d was unaffected (Supplemental Figure 3, A 
and B). Previous in vivo studies showed that siRNA localizes predominantly in peribronchial epithelial cells 
after intranasal administration to mice (25). Thus, Fbln1c was likely downregulated, at least in these cells. 
siRNA treatment completely inhibited chronic CS–induced decreases in total and soluble lung collagen and 
Col1a1 levels, which were restored to the levels in controls (Figure 4, A and B). There was a corresponding 
reversal of  collagen deposition around small airways (Figure 4C). siRNA treatment also suppressed 
emphysema-like alveolar enlargement (Figure 4D and Supplemental Figure 3C). These improvements in 
pathological features also protected against changes in lung function (Figure 4, E and F).
Fbln1c is required for interactions with its binding proteins to generate collagen. Fbln1 is important for ECM 
stabilization; therefore, its role in the deposition of  collagen and tissue remodeling in experimental COPD 
was determined. Eight weeks of  CS exposure of  WT mice resulted in increases in protein levels of  Fn, 
whereas Tnc remained the same in whole lung tissue (Figure 5A). These levels were significantly reduced 
in Fbln1c–/– mice. Decreased CS-induced Postn protein levels in WT mouse lungs were restored to control 
levels in Fbln1c–/– mice. Similarly, treatment with siRNA against Fbln1 during CS exposure also returned Fn 
and Postn to control levels but had no effect on Tnc protein amounts (Supplemental Figure 4).
We then determined the effects of  Fbln1c on the distribution of  the other ECM proteins during 8 
weeks of  CS exposure. In CS-exposed Fbln1c–/– mice, levels of  both Fn and Tnc were markedly reduced 
around the small airways, whereas Postn was increased compared with levels in CS-exposed WT controls 
(Figure 5, B–D and Supplemental Figure 5). Versican (Vcan), hyaluronan and proteoglycan link protein 
(Hapln1), and ECM1 protein levels were not altered in CS-exposed mice, nor were they dependent on the 
presence of  Fbln1c (Supplemental Figure 6).
Figure 1. Fbln1 is increased in human COPD patients and cigarette smoke–induced (CS-induced) experimental COPD in mice. Primary bronchoepithelial 
cells (pBECs) and serum were collected from COPD patients, non-COPD smokers, and nonsmoking healthy controls. (A) Fbln1 protein in pBEC lysates 
assessed by immunoblot (left), and fold change of densitometry normalized to GAPDH (right). n = 5–9. (B) Fbln1 protein in serum by immunoblot (left), 
and fold change of densitometry normalized to total protein (right). n = 8–9. *P < 0.05 compared with human nonsmoking control, unpaired 2-tailed 
Student’s t test. WT mice were exposed to CS for 8 weeks to induce experimental COPD; controls were exposed to normal air. n = 5–6. (C) Time course of 
total (left) and soluble collagen (right) in whole lungs. (D) Time course of collagen deposition around airways in lung sections stained with Verhoeff’s-Van 
Gieson (VVG, left; scale bar: 50 μm) and quantified by normalization to perimeter of basement membrane (Pbm) (right). n = 24–40 airways from n = 4–6 
mice per group. (E) Fbln1 protein in mouse lungs by immunoblot (top), and fold change of densitometry normalized to β-actin (bottom). n = 5–6. (F) Time 
course of Fbln1 protein around small airways by IHC (left; scale bar: 50 μm), and quantification normalized to Pbm (right). n = 24–32 airways from n = 4–6 
mice per group. (G) Time course of Fbln1 protein in serum, and fold change of densitometry normalized to total protein. n = 5–6. Results are mean ± SEM. 
*P < 0.05 compared with human nonsmoking control or normal air–exposed WT mice controls. ##P < 0.01 compared with non-COPD smokers. Statistical 
differences were determined with 1-way ANOVA followed by Bonferroni post-test.
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Next, we investigated the relationship between Fbln1, its interacting partners, and collagen around 
small airways after 8 weeks of  CS exposure. Fbln1, Fn, Tnc, Postn, and Col1a1 proteins colocalized around 
small airways after CS exposure and were markedly decreased in Fbln1c–/– mice (high magnification, Figure 
5, E–G, low magnification Supplemental Figure 7–9).
Fbln1c promotes inflammation in experimental COPD. As ECM protein production and remodeling can 
affect inflammation (26), leukocyte responses and proinflammatory molecular signals were examined in 
CS-exposed WT and Fbln1c–/– mice.
Eight weeks of  CS exposure resulted in increases in total leukocyte numbers dominated by mac-
rophages and neutrophils in BALF in WT mice compared with normal air–exposed controls, whereas 
Fbln1c–/– mice showed significantly reduced numbers of  these inflammatory cells (Figure 6A).
Eight weeks of  CS exposure induced increases in the levels of  proinflammatory cytokines TNF-α 
and IL-33, the fibrotic cytokine TGF-β, and the chemokine CXCL1 in the lung tissue of  WT mice. 
Each of  these factors is important in COPD pathogenesis (27). CS-exposed Fbln1c–/– mice had 
significant reductions in all of  these factors in lung tissues (Figure 6, B–E). However, there were no 
differences in protein levels of  these inflammatory factors in BALF between WT and Fbln1c–/– mice, 
whether they were exposed to CS or not (Supplemental Figure 10, A–C). In addition, TGF-β was 
undetectable in BALF.
As genetic depletion of  Fbln1c throughout CS exposure reduced inflammation, the therapeutic effect 
of  siRNA knockdown in WT mice was assessed. Fbln1c siRNA knockdown led to a selective decrease in 
BALF neutrophils (Figure 6F). Fbln1c knockdown did not affect lung TNF-α, IL-33, or TGF-β protein levels; 
however, concomitant with the reduction in neutrophils, CXCL1 levels were selectively decreased (Figure 
6, G–J). Therapeutic siRNA treatment did not affect BALF cytokine levels (Supplemental Figure 10, D–F).
Since the Smad family of  proteins — particularly Smad2, -3, and -4 — are important in downstream 
TGF-β signalling (28), we measured the mRNA levels of  these factors in the lungs of  WT and Fbln1c–/– 
mice after 8 weeks of  CS exposure (Supplemental Figure 11). CS exposure did not affect Smad2 mRNA 
levels in WT and Fbln1c–/– mice. Smad3 and Smad4 mRNA levels were also reduced in WT mice, but this 
reduction did not occur in Fbln1c–/– mice.
Figure 2. Generation of Fbln1c–/– mice. (A) 
Mouse Fbln1 gene diagram with alternatively 
spliced exons that encode the C-terminal 
variable domains of the Fbln1c and -d variants. 
(B) Expanded region of Fbln1 gene showing 
exons 15–18. (C) Targeted Fbln1 allele following 
recombination including the Neo cassette. 
Gray triangles indicate loxP sites used to 
remove the Neo cassette. Southern blots of 
genomic DNA from an ES cell clone transfected 
with exon 15 targeting vector. (D) Probe1 was 
hybridized to EcoRV digested genomic DNA. 
The 9.8-kb fragment is from the WT allele, 
and the 6.8-kb fragment is from the targeted 
allele. (E) Probe2 was hybridized to ApaI 
digested DNA. The 10-kb fragment is derived 
from the WT allele and the 8.2 kb from the 
targeted allele. (F) PCR of genomic DNA from 
mice +/+, +/–, and –/– for the deletion of exon 15 
and lacking the Neo cassette. (G) Reverse-
transcriptase PCR of RNA from hearts of E13.5 
WT embryos and embryos heterozygous and 
homozygous for the targeted deletion.
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Deletion of  Fbln1c in mice inhibits airway and lung remodeling in chronic asthma and lung fibrosis. Since airway 
inflammation and remodeling are also important features of  other chronic lung diseases, including asthma 
and IPF, the effect of  the absence of  Fbln1c on experimental models of  these diseases was assessed. Mice were 
chronically treated with HDM extract intranasally for 5 days per week for 5 weeks, which resulted in increased 
lung inflammation (low magnification, Figure 7A) and collagen deposition around airways in WT mice (high 
magnification). In other groups, bleomycin-induced lung fibrosis was induced and assessed 28 days later (lung 
fibrosis at low magnification and collagen deposition around airways at high magnification, Figure 7B). In 
both models, collagen deposition around small airways was completely inhibited in Fbln1c–/– mice.
Discussion
The respiratory diseases COPD, severe asthma, and IPF are among the most common and serious human 
diseases of  today. They are difficult to treat, and there are no currently available broadly effective treatments. 
The identification of  novel therapeutic targets may lead to the development of  new treatments. Increased 
Figure 3. Absence of Fbln1c protects against airway and lung remodeling, emphysema-like alveolar enlargement, and impaired lung function in 
experimental COPD. WT and Fbln1c–/– mice were exposed to cigarette smoke (CS) for 8 weeks to induce experimental COPD; controls were exposed 
to normal air. (A) Total (left) and soluble collagen (right) in whole lungs. n = 5–6. (B) Type I collagen (Col1a1) protein in whole lung tissues assessed by 
immunoblot (left), and fold change of densitometry normalized to β-actin (right). n = 5–6. (C) Collagen deposition around small airways in mouse lung 
sections stained with Verhoeff’s-Van Gieson (VVG, left; scale bar: 50 μm; inserts show expanded image of indicated regions; scale bar: 15 μm), and 
quantification is normalized to the perimeter of basement membrane (Pbm, right). n = 24–40 airways from n = 4–6 mice per group. (D) Col1a1 area 
around mouse small airways normalized to the Pbm. n = 24–40 airways from n = 4–6 mice per group. (E) α-Smooth muscle actin–positive (SMA-positive) 
cell (red) and nuclear staining (hoechst, blue) around small airways by immuofluorescence (top; SA, small airway; BV, blood vessel; scale bar: 50 μm), 
and quantification is normalized to the Pbm (bottom). n = 24–40 airways from n = 4–6 mice per group. (F) Emphysema-like alveolar enlargement was 
measured by assessment of alveolar diameter. n = 5–6. Lung function was measured in terms of (G) pressure-volume loops and peak volumes and (H) 
static lung compliance. n = 5–6. Results are mean ± SEM. *P < 0.05, **P < 0.01, ****P < 0.0001 compared with normal air–exposed WT or Fbln1c–/– 
controls. #P < 0.05, ##P < 0.01, ###P < 0.001 compared with CS-exposed WT controls. Statistical differences were determined with 1-way ANOVA followed 
by Bonferroni post-test.
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production of  ECM proteins can have serious pathological consequences in these and other diseases. Here, 
we discover important roles for the ECM protein Fbln1 in airway and lung remodeling, and also in driv-
ing inflammation in COPD. Fbln1 protein is elevated in pBECs and serum from COPD patients and in 
a chronic CS-induced mouse model of  experimental COPD. Genetic or therapeutic inhibition of  Fbln1c 
reversed decreases in collagen in lung parenchyma, likely as a result of  protecting against emphysema in 
CS-exposed WT mice. It also inhibited the increase in collagen deposition around the small airways in experi-
mental COPD. Fbln1c also contributes to chronic inflammation, as Fbln1c–/– mice were protected against 
CS-induced inflammatory cell influx into BALF and proinflammatory cytokine and chemokine production 
in the lungs. Accordingly, lung function was improved in CS-exposed Fbln1c–/– mice. Thus, targeting Fbln1c 
suppressed hallmark features of  airway and lung remodeling, emphysema, and inflammation and improved 
lung function in experimental COPD. It also suppressed airway remodeling in experimental chronic asthma 
and pulmonary fibrosis.
We found increased levels of  Fbln1 in pBECs and serum from COPD patients, as well as in the airway 
epithelium and lung tissue in experimental COPD. This extends other observations in which Fbln1 was 
increased in the serum of  asthma (13) and IPF patients (15), suggesting that Fbln1 may be a biomarker 
and therapeutic target in respiratory diseases and other conditions involving remodeling and inflammation.
Figure 4. Fbln1c siRNA protects against airway and lung remodeling, emphysema-like alveolar enlargement, and impaired lung function in 
experimental COPD. WT mice were exposed to CS for 8 weeks to induce experimental COPD and were treated with Fbln1c or scrambled siRNA. (A) Total 
(left) and soluble collagen (right) in whole lungs. n = 4–6. (B) Col1a1 protein in whole lungs (left), and fold change of densitometry normalized to β-actin 
(right). n = 4–6. (C) Collagen stained with VVG (left; scale bar: 50 μm) and normalized to Pbm (right). n = 4–6. (D) Emphysema-like alveolar enlargement. 
n = 4–6. Lung function in terms of (E) pressure-volume loops and peak volumes and (F) static lung compliance. n = 4–6. Results are mean ± SEM. 
 *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with normal air–exposed WT; $P < 0.05, $$P < 0.01 compared with CS-exposed controls 
treated with scrambled siRNA. Statistical differences were determined with 1-way ANOVA followed by Bonferroni post-test.
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We did not observe altered Fbln1 protein levels in primary fibroblasts from excised lungs from mild 
to moderate COPD patients compared with non-COPD controls with lung cancer (data not shown). A 
more in-depth study of  fibroblasts that includes the examination of  non-COPD, non–lung cancer controls 
is needed to clarify the roles of  these cells in Fbln-related events. Several types of  mesenchymal cells are 
Figure 5. Fbln1c binding proteins are altered in whole lungs and 
around small airways in WT and Fbln1c–/– mice with experimental 
COPD. WT and Fbln1c–/– mice were exposed to cigarette smoke for 8 
weeks to induce experimental COPD; controls were exposed to normal 
air. (A) Fibronectin (Fn), tenascin-c (Tnc), and periostin (Postn) protein 
levels in whole lungs assessed by immunoblot (left), and fold change 
of densitometry normalized to β-actin (right). (B) Fn, (C) Tnc, and (D) 
Postn area around the small airways analyzed by IHC and normalized to 
perimeter of basement membrane (Pbm). n = 24–40 airways from n = 
5–6 mice per group. (E) Colocalization of Tnc (blue), Col1a1 (green), and 
Postn (red) around the small airways. (F) Colocalization of Tnc (blue), 
Fbln1 (green), and Postn (red). (G) Colocalization of Fn (blue), Fbln1 
(green), and Postn (red) (scale bar: 15 μm. n = 3.). Results are mean ± 
SEM. *P < 0.05, **P < 0.01 compared with air–exposed WT or Fbln1c–/– 
controls; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with CS-exposed 
WT controls. Statistical differences were determined with 1-way ANOVA 
followed by Bonferroni post-test.
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capable of  producing Fbln1, and in the airways and lungs, there is likely not a single cellular source. In 
previous studies, we showed that ASM cells (13) and fibroblasts (14, 17) produce Fbln1. We also showed 
that Fbln1 is not upregulated by TGF-β (17), but TGF-β–stimulated fibroblasts can incorporate exog-
enously produced Fbln1 into the ECM. Furthermore, Fbln1c1 peptide promotes the production of  new 
Fbln1c1 in fibroblasts (14). Taken together, our studies indicate that soluble Fbln1c may be produced by 
cells, such as epithelial cells, and is incorporated into the airway by fibroblasts, especially when levels of  
profibrotic stimuli are increased, as occurs in COPD. This newly incorporated Fbln1 can then act as a 
stimulus for further ECM deposition, establishing a cycle of  persistent fibrosis. This could be interrupted 
with therapeutic intervention.
Eight weeks of  CS exposure to induce experimental COPD increased the levels of  protein but 
decreased mRNA expression of  Fbln1 in lung tissues. These discrepancies could be due to numerous 
factors, including alterations in DNA methylation, mRNA stability, and microRNA regulation. Our 
previous studies show that TGF-β downregulated Fbln1 mRNA in ASM cells and that Fbln1 protein was 
translationally controlled (17). We also found that TGF-β induced sequestration of  soluble Fbln1 into 
the ECM, rather than regulating de novo synthesis of  Fbln1. Smads are important downstream factors 
in TGF-β signaling pathways. Smad3 and Smad4 are downregulated in primary fibroblasts from COPD 
patients after CS extract challenge, whereas they are not changed in these cells from healthy controls (28). 
Other studies show that Smad3 is decreased in airway epithelial and stromal cells from COPD patients 
compared with controls (29) and Smad3-null mice develop spontaneous emphysema (30). We demonstrate 
in this study that WT mice with experimental COPD had reduced Smad3 and Smad4, whereas Fbln1c–/– 
mice did not. This may explain why emphysema-like alveolar enlargement did not occur in Fbln1c–/– mice 
exposed to CS for 8 weeks, although the exact mechanisms involved remain unclear.
Increases in Fbln1 protein were associated with pulmonary remodeling, emphysema, and inflammation, 
which were reduced in Fbln1c–/– mice. This shows that CS affects Fbln1 homeostasis, increasing its 
production and likely modifying its degradation and peptide generation. Fbln1c peptides can stimulate 
Fbln1 deposition in COPD fibroblasts — potentially through a feed-forward mechanism — and promote 
Figure 6. Absence of Fbln1c protects against inflammation in experimental COPD. WT and Fbln1c–/– mice were exposed to cigarette smoke (CS) for 
8 weeks to induce experimental COPD; controls were exposed to normal air. (A) Differential inflammatory cell counts in bronchoalveolar lavage fluid 
(BALF). (B) TNF-α, (C) IL-33, (D) TGF-β, and (E) CXCL1 protein in whole lungs measured by ELISA. WT mice were treated with Fbln1c or scrambled siRNA 
from weeks 6–8 of 8 weeks of CS exposure. (F) Differential inflammatory cell counts in BALF. (G) TNF-α, (H) IL-33, (I) TGF-β, and (J) CXCL1 protein in 
whole lungs. Results are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with normal air–exposed WT or Fbln1c–/– controls; 
#P < 0.05, ##P < 0.01, ####P < 0.0001 compared with CS-exposed WT controls; $P < 0.05 compared with CS-exposed controls treated with scrambled 
siRNA. Statistical differences were determined with 1-way ANOVA followed by Bonferroni post-test.
Downloaded from http://insight.jci.org on February 28, 2017.   https://doi.org/10.1172/jci.insight.86380
1 0insight.jci.org   doi:10.1172/jci.insight.86380
R e s e a R c h  a R t i c l e
the attachment of  ASM cells and fibroblasts; they also augment Fn and perlecan deposition (14). Some 
proteases, such as MMP13, cleave Fbln1 (31, 32), and the mRNA expression of  this enzyme is upregulated 
in CS-exposed mice (Supplemental Table 1). Thus, there is the potential that increases in MMP13 and 
Fbln1 levels promote airway remodeling but also produce more cleavage products, inducing inflammation, 
as is the case with other ECM factors (33). It is possible that the increase in MMP13 was insufficient to 
control the levels of  Fbln1c produced in response to CS exposure. However, this would result in the release 
of  greater levels of  fragments of  Fbln1c that may further increase inflammatory responses. There were 
no differences in mRNA expression of  MMP13 in the lungs between CS-exposed WT and Fbln1c–/– mice, 
and the role of  this protease needs further study. The calcium-binding protein calumenin protects Fbln1 
from MMP13 cleavage, which in turn suppresses the phosphorylation of  extracellular signal–regulated 
kinases 1 and 2 (ERK1/2) and cell migration (32). However, calumenin expression was not altered in 
CS-exposed mice (data not shown), suggesting that it is unlikely to be protecting against Fbln1 degradation. 
Thus, although the exact mechanisms are unknown, it is likely that Fbln1 is constantly being produced and 
degraded, and when in excess, this leads to remodeling and inflammation.
To further assess mechanisms, primary fibroblasts from WT and Fbln1c–/– mice were isolated and 
exposed to CS extract. Supernatants were collected and added to cultures of  BM-derived macrophages 
from WT and Fbln1c–/– mice. The release of  cytokines and chemokines (TNF-α and CXCL1) was assessed, 
but we found no differences in response to exposure or between mouse strains. Microarray and proteomics 
analyses could be employed to further investigate the mechanisms involved, along with the ways in 
which the Fbln1c signal is sensed and how a response program is initiated, which would be important 
future directions. Furthermore, a more detailed dissection of  the synthesis, secretion, and turnover of  the 
associated ECM elements in the airway and parenchyma would facilitate the elucidation of  how Fbln1c 
stabilizes collagen.
Fibrillar collagen is a major structural component of  ECM and is important in maintaining tissue 
integrity (34). We observed CS-induced reductions in collagen levels in the parenchyma, which was 
Fbln1 dependent and likely contributes to loss of  alveolar tissue. Human studies using microcomputed 
tomography show that the amount of  collagen in lung tissue and respiratory bronchioles — the regions 
associated with emphysema — decreases in patients with more severe COPD (35). This suggests that 
Figure 7. Absence of Fbln1c protects against airway remodeling in experimental chronic asthma and pulmonary fibrosis. WT and Fbln1c–/– mice were 
administered house dust mite (HDM) extract for 5 days per week for 5 weeks; controls were administered sterile saline. (A) Collagen deposition around small 
airways in lung sections stained with Verhoeff’s-Van Gieson stain (VVG, left; scale bar: 500 μm). Inserts show expanded image of indicated regions (scale 
bar: 50 μm). Quantification of collagen deposition normalized to the perimeter of basement membrane (Pbm) (right). n = 24–40 airways from n = 6–8 mice 
per group. WT and Fbln1c–/– mice were administered bleomycin sulphate once, controls were administered sterile PBS, and tissues were collected 28 days 
later. (B) Collagen deposition around small airways and normalized to Pbm (scale bar: 500 μm). Inserts show expanded image of indicated regions (scale 
bar: 50 μm). n = 24–32 airways from n = 8 mice per group. Results are mean ± SEM. **P < 0.01 compared with WT or Fbln1c–/– controls; #P < 0.05, ##P < 0.01 
compared with HDM or bleomycin-treated WT controls. Statistical differences were determined with 1-way ANOVA followed by Bonferroni post-test.
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alveolar collagen loss increases with COPD severity. Since mice do not have respiratory bronchioles, the 
similar decreases in collagen in mice and humans likely occur in the terminal bronchioles.
Paradoxically, we found Fbln1-dependent increases in collagen around the small airways in experimental 
COPD. A similar phenomena occurs in the lungs in severe COPD, where regions of  bronchiolar tissue 
destruction are closely associated with the thickening of  airway tissue (35). It is surmised that fibrotic 
repair mechanisms are initially induced in both tissues; however, chronic stimulation results in a switch to 
an antifibrotic phenotype in the parenchyma only. Thus, inverse alterations in collagen levels in different 
Figure 8. Schematic diagram of the role of Fbln1c in lung remodeling and inflammation. Lung injury, smoke, or 
allergen exposure increases Fbln1c in airways and parenchyma. This stabilizes fibronectin, tenascin-c, and periostin 
and promotes collagen deposition. Excess collagen deposition induces lung and airway remodeling and impaired 
lung function. Fbln1c also promotes airway inflammation — involving the influx of macrophages, neutrophils, and 
lymphocytes — and increases in associated cytokines/chemokines that induce the production of ECM proteins and the 
development of respiratory disease.
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tissues may reflect advanced progression of  disease. Generally, acute CS exposure increases the expression 
of  profibrotic mediators in both the parenchyma and airways (36). Chronic exposure induces continuous 
low-grade inflammation and reduces gene expression of  matrix proteins and positive regulators of  matrix 
formation in the parenchyma only (36). This suggests that lung tissue is uniquely prone to these gene-
expression changes and emphysema development only after chronic CS exposure.
Thus, Fbln1c–/– mice are protected against abnormal deposition of  collagen in lungs in experimental 
COPD, although the mechanisms involved are unclear. In other assays, we found that the expression of  the 
common collagenases (MMP1, -3, and -8) and proteases (MMP7, -12, and -13) were not Fbln1c dependent 
(Supplemental Figure 12). Nevertheless, many other collagenases and proteases are present in the lungs, 
and their involvement requires further investigation. It is likely that unknown molecular and cellular factors 
that may have site-specific actions may also contribute to different effects in different tissues. This could 
be resolved by microdissection and omics analyses of  different tissues in WT and Fbln1c–/– mice with and 
without CS exposure. However, this is beyond the scope of  the current study.
To maintain lung structure and induce fibrosis, ECM proteins need to interact with each other in 
the correct confirmation. Our study shows that Fbln1 critically regulates these interactions during excess 
fibrosis in 3 respiratory diseases (Figure 8). Fbln1 directly interacts with other ECM proteins, including 
Fn (32, 37). Fbln1 binds to the Heparin II domain (38) and has cell-adhesion and motility-suppressive 
effects on Fn-coated substrates (39). Tnc has a binding domain similar to that of  Fbln1 and could bind 
with Fn (40). Furthermore, Postn and Fn bind to collagen, and Fbln1, Tnc, and Postn colocalize in skin 
keratinocytes (11, 41, 42). Fn, Tnc, and Postn have altered protein expression in Fbln1c–/– mice, indicating 
that Fbln1 directly or indirectly binds to multiple targets and organizes collagen structure in COPD. This 
may result from the dysregulation of  RNA or altered secretion/deposition. However, as the “matrisome” 
that makes up and regulates ECM is extensive (>1,000 proteins) (43), other proteins are likely involved, and 
their elucidation would be a major undertaking and requires further research.
Alterations in individual ECM proteins changes the overall physical properties of  the matrix affecting 
cell movement and function, local macromolecule activity, and the ability to bind cytokines and contrib-
ute to inflammation. In chronically inflamed tissues, such as COPD-patient lungs, aberrant ECM protein 
expression and fragment generation affects cellular motility and promotes immune responses (26). Collagen-
derived peptide fragments, in particular proline-glycine-proline (PGP), are increased in the lungs of  COPD 
patients and contribute to inflammation through the chemoattraction of  neutrophils (44). The stabilization 
of  collagen levels in Fbln1c–/– mice may contribute to the reduction in neutrophil influx and numbers.
Previous studies demonstrated that remodeling and inflammation are interdependent (45). We consider 
that Fbln1 induces remodeling and inflammation likely through such interdependent processes that, in 
combination, promote the phenotype observed. We demonstrate here that Fbln1c–/– mice have reduced 
cellular inflammation in the airways and decreased levels of  the proinflammatory cytokines TNF-α 
and IL-33; a profibrotic cytokine involved in airway remodeling (46, 47); and the chemokine CXCL1 
in the lungs. This may be the result of  a direct effect on cellular expression of  these cytokines and/or 
chemokines, or it may occur indirectly through reductions in other immunomodulatory factors that control 
their expression, such as Tnc. Alterations in other ECM proteins also affects inflammation. Tnc–/– and 
Postn–/– mice have reduced inflammation in models of  asthma and lung fibrosis, respectively (48, 49). Tnc 
is regulated by both the spatial and temporal distribution of  Fbln in chronic contact dermatitis (50) and is 
an activator of  TLR4-mediated immunity that facilitates persistent inflammation and tissue destruction in 
arthritic joint disease (51). Thus, the reduced levels of  Tnc shown here in both the parenchyma and airways 
in CS-exposed Fbln1c–/– mice could contribute to the decreases in TNF-α and CXCL1 production, affecting 
neutrophil chemotaxis.
Airway remodeling is an important feature of  other respiratory diseases, including asthma and IPF. We 
show that Fbln1c–/– mice have reduced collagen deposition around the airways in chronic allergic airways 
disease and lung fibrosis mouse models. Experiments determining the mechanisms involved in these 
models are currently ongoing. This shows that Fbln1 is a critical mediator of  fibrosis in multiple models of  
airway remodeling induced by different factors.
Our data show that the Fbln1c isoform affects remodeling and inflammation in respiratory diseases. 
Unlike mice, humans also have Fbln1a and -b. Fbln1 has 3 domains (I, II, and III). All Fbln1 variants 
contain domain I and II, and the only difference is their domain III, which is localized in their C- terminus 
(52). Fbln1a does not have the C-terminal domain and that domain in Fbln1b is shorter and therefore is 
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likely less functional than in Fbln1c. Furthermore, Fbln1a and -b are developmentally expressed and are 
not typically found in adults. Thus, it is unlikely that Fbln1a and -b compensate for Fbln1c in humans. 
Fbln1d also does not appear to compensate, since its expression did not increase when Fbln1c was inhibited 
with siRNA in mice (Supplemental Figure 1C).
Collectively, our data show that Fbln1, especially Fbln1c, plays important roles in the pathogenesis of  
COPD. Fbln1 regulates airway and parenchymal collagen deposition by organizing ECM proteins, promot-
ing airway remodeling and emphysema; it also induces inflammation, and these events lead to a reduction in 
lung function. Fbln1 also promotes airway remodeling in other models of  chronic respiratory disease. This 
identifies Fbln1 as a potential therapeutic target in chronic airway and potentially other fibrotic and inflam-
matory diseases and warrants further investigation.
Methods
Human subjects. Nine patients were recruited with stage III severe COPD with forced expiratory volume in 
1 second (FEV1) 30%–50% COPD and classified according the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) criteria (Supplemental Table 2) (53). They were defined by fixed airflow limitation 
on spirometry with an FEV1/forced vital capacity (FVC) ratio less than 70%, and FEV1 less than 80% 
predicted. All were ex-smokers (at least 1 year abstinent) and none were using inhaled corticosteroids for 
2 weeks before bronchoscopy. Eight healthy nonsmoking controls and 5 non-COPD current smokers were 
also recruited. They had no evidence of  airflow obstruction, bronchial hyperresponsiveness to hypertonic 
saline challenge, or chronic respiratory symptoms. Clinical examination and spirometry were performed 
on all individuals, whom were also questioned about the previous severity of  cold symptoms. At the time 
of  recruitment, none of  the subjects had symptoms of  acute respiratory tract infections for the preceding 4 
weeks and did not have a diagnosis of  lung cancer.
Isolation of  pBECs. Human pBECs were obtained by endobronchial brushing during bronchoscopy in 
accordance with standard guidelines (54). pBECs were cultured in hormone-supplemented bronchial epi-
thelial growth medium (BEGM, Lonza) supplemented with 50 U/ml penicillin and streptomycin as previ-
ously described (55–57). All subjects gave written informed consent.
Fbln1c targeting vector. A genomic clone approximately 14 kb in length containing exon 15 encoding the 
carboxyl terminal domain of  Fbln1c was isolated from a 129/SvEvTacfBr mouse genomic library (Agilent 
Technologies). The clone was digested with the restriction enzymes EcoRV and XhoI to release a 6.8-kb 
fragment located approximately 1.1 kb upstream of  exon 15 (Figure 2). XhoI linkers were added to the 
6.8-kb fragment, which was subsequently cloned into a XhoI site located downstream of  a HSV-tk gene to 
create the 5′ homologous long arm of  the targeting vector. The 3′ homologous arm of  the targeting vector 
was obtained by digestion of  the genomic clone with HindIII and SpeI to release a 4.7-kb fragment located 
approximately 2 kb downstream of  exon 15. BamHI linkers were added, and the DNA was cloned into a 
BamHI site downstream of  a loxP Neomycin (Neo) loxP resistant gene. The resulting targeting vector was 
linearized with NotI and transfected into ES cells by electroporation. Transfected ES cells were grown on 
gelatin and selected for G418 resistance. Homologous recombinant clones were identified by Southern blot 
analysis using probes located outside of  the targeting region. Targeting of  the 5′ arm was confirmed by the 
presence of  a 9.8-kb fragment from the WT Fbln1 allele and a 6.8-kb fragment for the targeted Fbln1 allele 
following hybridization of  EcoRV-digested ES cell genomic DNA. Likewise, recombination of  the 3′ arm 
was confirmed by the presence of  a 10-kb fragment derived from the WT Fbln1 allele and an 8.2-kb band 
from the targeted Fbln1 allele following hybridization of  ApaI digested ES cell genomic DNA.
One homologous recombinant clone was expanded and injected into C57BL/6 blastocysts (Charles 
River Laboratories) and implanted into pseudopregnant females. The generated chimeric male mice were 
bred with 129S6/SvEvTac female mice (Taconic Biosciences), and their offspring were genotyped by PCR 
using the oligonucleotide primers 5′-GGCGCGAAGGGGCCACCAAAGAACGGAG-3′, 5′-GTGCTAA
GGTGAGAATAAGTTCTCTTAGTAGCATC-3′, and 5′-GCCTGATAAGCATCCAATAAGACACAA
AC-3′ to identify pups carrying the targeted Fbln1 allele. To excise the loxP Neo loxP cassette, male offspring 
carrying the targeted Fbln1 allele were mated to female ZP3-Cre mice (C57BL/6-Tg[Zp3-cre]93Knw/J, 
catalog 003651, The Jackson Laboratory) as previously described (58). Pups from the resulting cross 
were screened by PCR for the Cre-mediated recombination event using oligonucleotide primers 
5′-GCCTGATAAGCATCCAATAAGACACAAAC-3′, 5′-GGGCTGCAGGAATTCGATATC-3′, and 
5′-CAGGTTCTTACTTCCTGTGACAG-3′. Mice carrying the targeted Fbln1 allele following removal of  
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the Neo cassette were backcrossed to C57BL/6 mice for 5 generations.
Genotyping of  Fbln1c–/– mice. The genotypes of  offspring were determined from tail clip genomic 
DNA by PCR using 3 oligonucleotide primers. To detect the WT Fbln1 allele, PCR was performed using 
5′-GCCTGATAAGCATCCAATAAGACACAAAC-3′ and 5′-CAGGTTCTTACTTCCTGTGACAG-3′. 
To detect heterozygous and homozygotes mice, the former primer was used with 5′-GGGCTGCAG-
GAATTCGATATC-3′. Cycling parameters for PCR were: 39 cycles of  95°C for 50 seconds, 53°C for 30 
seconds, and 72°C for 2 minutes. The expected size for the amplicons produced from the WT allele is 532 
bp, and the expected size  from the targeted Fbln1c allele is 440 bp.
Detection of  Fbln1 variants. Total RNA was isolated from tissues using TRIzol (Invitrogen) and an RNeasy 
Mini Kit (QIAGEN). cDNA was prepared from total RNA using the iScript cDNA synthesis kit (Bio-Rad) 
according to the manufacturer’s specifications. cDNA preparations were diluted to 25–50 μl, and 2 μl ali-
quots were used in PCR reactions. Oligonucleotide primers used in PCR reactions were 5′-GCCCTCCT-
CATTGCCAGCGGTGATGGC-3′ (Fbln1c transcript), 5′-GGAGTCTCGAAGGTTCCCTTCTGT-
GATG-3′ (Fbln1d transcript), and 5′-CCCAATGGCCGCAACTGCCAAGACATTG-3′ (common primer 
for Fbln1c and Fbln1d). To detect Fbln1c and Fbln1d variants, all 3 primers were used with the following 
cycling parameters: 29 cycles of  95°C for 50 seconds, 65°C for 45 seconds, and 72°C for 1 minute. The 
expected size for the amplicons produced from Fbln1c is 300 bp and the expected size for Fbln1d is 380 bp.
Experimental mouse models and interventions. Six- to 8-week-old female WT or Fbln1c–/– C57BL/6J 
mice (Medical University of  South Carolina) were exposed to twelve 3R4F cigarettes (University of  
Kentucky) using a custom-designed and purpose-build nose-only smoke system (CH Technologies) twice 
per day with at least 90 minutes of  rest in between, as previously described (18–22). They were exposed 
either for 4 days or 5 times per week for 4, 6, or 8 weeks.
Fbln1c siRNA (sense: 5′-CUGCAAAGAUAUUGACGAAUU-3′, antisense: 5′-UUCGUCAAU-
AUCUUUGCAGUU-3′), and negative control scrambled siRNA (sense: 5′-UGGUUUACAUGUUGU-
GUGAUU-3′, antisense: 5′-UCACACAACAUGUAAACCAUU-3′) were obtained from Dharmacon. 
Mice were treated intranasally with 40 μg of  either Fbln1c or scrambled siRNA 2 hours before CS exposure 
every second day for 4 days or 3 times per week from week 6–8 of  exposure.
Experimental chronic asthma was induced by intranasal administration of  house dust mite (HDM) 
extract (Greer Laboratories) at 25 μg in sterile saline as described previously (59). Control mice received 
sterile saline only. HDM was administered for 5 consecutive days per week for 5 weeks.
Experimental pulmonary fibrosis was induced by intranasal administration of  one dose of  bleomycin 
sulphate (MP Biomedical) at 0.05 U/mouse as described previously (60). Control groups received an equal 
volume of  sterile PBS. Tissue collection was performed 28 days after bleomycin treatment.
BALF. Mouse mutilobed lungs were tied off, and BALF was collected from the single-lobed lung by 
washing twice with PBS (500 μl). Cells were pelleted (150 g, 10 minutes) and resuspended in rbc lysis buffer. 
Remaining cells were cytocentrifuged (300 g, 5 minutes, ThermoFisher Scientific) onto microscope slides. 
BALF slides were stained with May-Grunwald-Giemsa, and differential counts were enumerated accord-
ing to morphological criteria using light microscopy as previously described (61).
Lung RNA extraction and real-time PCR. Whole lungs were excised and homogenized using a tissue-
tearor stick homogenizer (BioSpec). Total RNA was extracted using TRIzol (Invitrogen) according to the 
manufacturer’s instructions (62). RNA (1,000 ng) from whole lungs was reverse transcribed using Bioscript 
(Bioline) and random hexamer primers (Invitrogen) (63). The mRNA expression of  Col1a1, Fbln1c, Fbln1d, 
Smad2, Smad3, Smad4, MMP1, MMP3, MMP7, MMP8, MMP12, and MMP13 (Supplemental Table 3) was 
determined using real-time PCR and a Viia 7 real-time PCR system (Invitrogen) and compared with the 
reference gene hypoxanthine-guanine phosphoribosyltransferase (HPRT).
ECM array. RNA was extracted from mouse lung tissues and reversed transcribed to cDNA. cDNA were 
hybridized to an RT2 profiler Mouse Extracellular Matrix PCR array (QIAGEN) that contained 84 ECM-
specific genes and housekeeping genes. PCR was performed according to the manufactures’ instructions. 
RT2 Profiler PCR Array Data Analysis software (version 3.5, QIAGEN) was used to normalize Ct 
amplification values to housekeeping genes. Data were expressed as ΔΔCt, and fold-change was compared 
with normal air–exposed controls.
Airway remodeling. Mouse lungs were perfused with 0.9% saline and formalin fixed, and sections were 
cut to 4-μm thickness. Slides were deparaffinized with xylene and a graded ethanol series. Collagen was 
stained with Verhoff ’s-Van Gieson (VVG) stain (Australian Biostain). Photomicrographs were taken and 
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images were evaluated with Image J (version 1.47) as previously described (20, 22).
Briefly, at least 6 airways per mouse were blind-selected, and those from 4–6 animals in each experimental 
group were examined with a light microscope (BX41, Olympus). Morphometric parameters were marked 
manually on the digital representation of  the airways using Image-pro plus software (version 7). Airways 
were divided into 3 categories according to the perimeter of  their basement membrane (Pbm): Pbm ≤ 1 mm 
(small), Pbm ≤ 2 mm (medium), and Pbm > 2mm (large) (64).
The width of  Pbm, the inner collagen area (Ai), and the outer collagen area (Ao) were manually measured 
using Image J. The collagen area (Wct) was calculated (Wct = Ao – Ai) and normalized to the Pbm.
Emphysema-like alveolar enlargement. Emphysema was assessed using the mean linear intercept technique 
as previously described (57). Briefly, random images of  H&E-stained lung sections were captured under ×40 
magnification. An 11–horizontal line template was used to overlay the first 10 images that did not contain 
airways and/or blood vessels. Intercepts of  alveolar walls with lines were enumerated and alveolar diameter 
calculated by dividing the total length of  the 11 lines by the average number of  intercepts per lung section.
Lung function. Static lung compliance was measured by quasistatic pressure-volume loops from Flexivent 
apparatus (Scireq) as previously described (65). Mice were anesthetized (50 μl/10 g i.p.) with a mixture 
of  xylazine (2 mg/ml, Troy Laboratories) and ketamine (40 mg/ml, Ceva). Cannulae were inserted into 
mouse tracheas after tracheostomy. Animals were ventilated with a tidal volume of  8 ml/kg at a rate of  450 
breaths/min, with increasing airway pressure from 2–30 cmH2O into the lung tissue. The volume of  air in 
the lung at the end of  maximal inspiration was determined. Static lung compliance was calculated as volume 
change divided by applied pressure change.
Hydroxyproline. Hydroxyproline content was used to quantify collagen in whole mouse lungs and was 
measured colorimetrically as described previously with modifications (66). Briefly, lung tissue was excised 
and snap frozen at –80°C. Wet lungs were weighed and homogenized in 6N HCl at 130°C for 8 hours. Five 
μl of  each sample was mixed with 5 μl of  citrate-acetate buffer (5% citric acid, 1.2% glacial acetic acid, 7.24% 
sodium acetate, and 3.4% sodium hydroxide). Chloramine-T solution (100 μl, 1.4% chloramine-T, 10% 
N-propanol, and 80% citrate-acetate buffer) was added, and samples were incubated at room temperature 
for 20 minutes. Ehrlich’s solution (100 μl, Sigma-Aldrich) was added, and the mix was incubated at 65°C 
for 18 minutes. Absorbance was measured at 558 nm, and concentrations were determined in comparison 
with standard curves generated using dilutions of  pure hydroxyproline (Sigma-Aldrich).
Soluble collagen. Soluble collagen in mouse lungs was determined using a Sircol Collagen Assay kit 
(Biocolor) according to the manufacturer’s instructions. Briefly, lungs were weighed and homogenized in 
pepsin (Sigma-Aldrich, 0.1 mg/ml in 0.5 M acetic acid) for 24 hours at 4°C. Supernatants were collected 
after centrifugation (150 g, 10 minutes). Sircol dye reagent was added with shaking for 30 minutes at room 
temperature and were again centrifuged. Pellets were suspended in alkali reagent from the kit. Optical 
density was measured at 550 nm, and the concentrations of  soluble collagen were compared with standard 
solutions and a standard curve provided by the manufacturers.
Protein extraction. Lung tissues were thawed and homogenized in RIPA buffer (Sigma-Aldrich) 
supplemented with PhosSTOP phosphatase inhibitor and complete protease inhibitor cocktails (Roche 
Diagnostics) as previously described (21, 22). Tissues were homogenized and centrifuged (8,000 g, 
10 minutes, 4°C), and proteins were collected for immunoblot or ELISA. Protein concentrations were 
determined using BCA protein assay kit (Pierce Biotechnology).
Immunoblotting. Proteins were subjected to SDS-PAGE using Mini-PROTEAN TGX Stain-Free gels (Bio-
Rad) and transferred to PVDF (EMD Millipore). Specific antibodies were used to detect Fbln1 (clone ab175204), 
Col1a1 (clone ab21286), and Postn (clone ab14041) (all fromAbcam); Fn (clone F3648, Sigma-Aldrich); and 
Tnc (clone sc-20932), Vcan (clone sc-25831), Hapln1 (clone sc-135184), and ECM1 (clone sc-135032) (all from 
Santa Cruz Biotechnology). β-Actin (clone ab70165) and GAPDH (clone ab9483) (both from Abcam) were 
used as loading controls. Images of immunoblots were captured with a ChemiDoc MP System (Bio-Rad). Some 
blots were cut based on the protein molecular weight. Thus, multiple proteins were detected at the same time. 
Some blots were stripped but only reprobed once in order to avoid background effects.
For lung and cell lysates samples, Image J was used for densitometry analysis as described previously 
(57). In brief, the densitometric values of  proteins of  interest were measured and normalized to the density 
of  the internal control proteins, such as β-actin or GAPDH. Values were represented as fold change of  the 
experimental compared with control groups.
For serum samples, a stain-free technology was employed for densitometry analysis using a ChemiDoc 
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MP System (Bio-Rad) as described previously (67). After electrophoresis, Mini-PROTEAN TGX Stain-Free 
gels were activated by ultraviolet light for visualization of  protein bands. The gels were then transferred to 
PVDF membranes, which were also visualized to capture stain-free images (ChemiDoc MP System; Bio-
Rad). For densitometry, all lanes including the molecular weight marker lanes as references were selected 
in the stain-free blot. A normalization factor was calculated by dividing the total intensity of  the stain-free 
reference lane by the whole intensity of  each lane. For Fbln1 immunoblots, the intensity of  the protein in 
each lane was measured and normalized with the normalization factor for each sample. The fold change of  
normalized volume in each treatment group was compared with control groups.
ELISA. TNF-α, IL-33, and CXCL1 (Duoset, R&D Systems) levels in lung tissues and BALF supernatants 
were assessed by ELISA according to the manufacturers’ instructions. TGF-β levels were determined using 
capture and detection antibodies (BD Pharmingen) according to manufacturer’s instructions. The target 
proteins in lungs were normalized to total lung protein.
Immunostaining. Lungs were perfused, inflated, formalin-fixed, paraffin-embedded, and sectioned (4–6 μm). 
Longitudinal sections were deparaffinized, incubated with citrate buffer for antigen retrieval, and blocked with 
casein (Sigma-Aldrich, room temperature, 1 hour). Slides were incubated with Fbln1 (1:40), Tnc (1:20), Postn 
(1:1,000), Col1a1 (1:200), and Fn (1:200) (4°C, overnight) followed by anti-rabbit horseradish peroxidase–
conjugated secondary antibody (R&D Systems, 37°C, 30 minutes). Diaminobenzidine (DAB, DAKO) was 
applied on slides, and hematoxylin was used as a counterstain. α-SMA–positive cells were stained with anti-
actin α-SM-Cy3 (1:200, clone c6198, Sigma-Aldrich), and nuclei were stained with Hoechst (Sigma-Aldrich).
Some mouse lungs were perfused and inflated with OCT medium and PBS at a 1:1 ratio. Tissues were 
immediately placed in OCT medium and rapidly frozen on dry ice. Frozen sections (5-μm) were cut and 
fixed in cold acetone for 10 minutes. After 2 hours of  blocking with 5% BSA (Sigma-Aldrich), slides were 
incubated with Col1a1, Tnc, Postn, Fbln1, and Fn antibodies with PE/Cy5 (clone ab102893), AMCA 
(clone ab102846), and FITC (clone ab102884) conjugation kits (all from Abcam) in different groups (4°C, 
overnight). Fluorescence signals were examined using confocal microscopy (Nikon C2), and all images 
were analyzed using NIS-Element software (Nikon).
Statistics. Results are presented as mean ± SEM from 4–8 sample size, each in duplicate or triplicate 
experiments. Comparisons between 2 groups were determined using unpaired 2-tailed Student’s t test, and 
multiple groups were performed by one-way ANOVA with Bonferroni post-test using Prism-GraphPad 
Software version 6 (GraphPad). Representative photomicrographs are shown throughout. Results are mean 
± SEM, where P less than 0.05 is considered significant.
Study approval. Human studies were approved by the Human Research Ethics Committee of  the 
University of  Newcastle. All mouse experiments were approved by the animal ethics committee of  the 
University of  Newcastle.
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